RxDoctor Payments Data

Robin Sutcliffe, APRN

Family · Lexington, KYNPI 1730490921

Payments from drug & device makers

$8,197in general payments, 2019–2025

Across 453 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$681
  • Johnson & Johnson$631
  • Novo Nordisk$351
  • Phathom Pharmaceuticals, Inc.$261
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$8,169100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,197 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$9,149
Medicare patients
70
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase11$99,491
CreonLipase/Protease/Amylase17$71,231
XifaxanRifaximin21$70,264
LinzessLinaclotide35$36,922
TrulancePlecanatide13$18,290
MotegrityPrucalopride Succinate18$14,485
Dexlansoprazole DrDexlansoprazole44$8,033
Ursodiol29$6,089
Lubiprostone25$5,071
Colestipol Hcl61$4,870
Pantoprazole Sodium151$3,100
Esomeprazole Magnesium28$1,831
Omeprazole81$911
Lactulose19$609
Famotidine39$589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,124$108,15352 claims
QOL Medical, LLCSucraid$193$99,49111 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,681$88,55334 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$681$14,48518 claims
SandozLansoprazole$25$45211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →